

# BioSig Technologies, Inc.

1 ? . Ž ( ( f \$ & \$ + - , - , \$ , %  
 B 5 . Ž % \* ( \* , - \* ' \$ \* )  
 5 1 Ž \* % & - & , \$ \$ + \$ \$  
 U W j c b 4 d f c U W j Y j b j Y g h c f g " V e a

10:30 13 Jan 2021

## BioSig unveils partnership with Vuzix which will see the latter's M400 Smart Glasses used for remote servicing of its PURE EP System

BioSig Technologies, Inc. (NASDAQ:BSGM) has announced a partnership with Vuzix Corporation (NASDAQ:VUZI), which will see the medical technology firm deploy Vuzix's M400 Smart Glasses for remote servicing of its PURE EP System.

The group said the deployment will support the planned nationwide rollout of BioSig's novel real-time signal processing platform to the large and growing electrophysiology market in the US. The remote servicing support offers an ideal solution for compliance with coronavirus (COVID-19) travel restrictions, it added.

"We are thrilled to work with Vuzix to deploy its outstanding smart glasses solution and enhance our technology offering as we work to accelerate commercialization of our PURE EP System nationwide," Kenneth L. Londoner, chairman & CEO of BioSig Technologies said in a statement.

### READ: BioSig Technologies says its PURE EP System has been installed and first patient cases conducted at Memorial Hospital of South Bend, Indiana

"The Vuzix M400s are the powerful enterprise smart glasses and have compelling clinical applications for digital healthcare. The addition of AR technology to our PURE EP System solution should give us an even greater opportunity to elevate the standard of care in the electrophysiology market," the BioSig CEO added.

The Vuzix M400 is the next evolution of the industry-leading Vuzix M-Series smart glasses, featuring the new Qualcomm Snapdragon(TM) XR1 platform. Vuzix was hand-selected as one of the initial launch partners for the new Snapdragon XR1 platform, the first purposely built, dedicated XR platform from Qualcomm Technologies. The Snapdragon XR1 microprocessor enables a combination of voice and touchpad navigation for complete control over the device. The M400 Smart Glasses improve processes within many applications such as warehouse logistics, telemedicine, manufacturing, and field service.

Equipped with Vuzix Remote Assist (VRA) software, the M400 Smart Glasses should provide BioSig's partner physicians and clinicians with quick remote access to technical experts who can assist with servicing the unique hardware architecture and digital modality of PURE EP Systems being utilized in the field. Enterprise use of the M400 Smart Glasses is intended to enable technicians to support BioSig's systems without the necessity of on-site visits, dramatically decreasing time and expense for both the Company and PURE EP System users.

BioSig plans to explore whether Vuzix Smart Glasses may be used to facilitate remote customer training and provide line-of-sight visualization of intracardiac signals during ablation procedures performed by physicians. In the healthcare industry, Vuzix Smart Glasses are already being used in hospitals and medical centers around the world to perform a

**Price:** 4.82

**Market Cap:** \$148.07 m

#### 1 Year Share Price Graph



January 2020 July 2020 January 2021

#### Share Information

**Code:** BSGM

**Listing:** NASDAQ

<b>52 week</b>	<b>High</b>	<b>Low</b>
	<b>12.43</b>	<b>2.37</b>

**Sector:** Medical technology & services

**Website:** [www.biosigtech.com](http://www.biosigtech.com)

#### Company Synopsis:

*BioSig Technologies, Inc. , a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

wide range of functions, including training, virtual rounds within ICUs, triage in the emergency room and the operating room to guide physicians during surgery, and to provide remote training and mentor remote doctors.

"BioSig' PURE EP System is an incredibly innovative solution that is tackling a tough problem, and we are proud to support this promising product," added Paul Travers, president and chief executive officer of Vuzix.

"Vuzix has deep experience working with medical and healthcare providers to support applications that have ranged from performing surgeries to telemedicine, patient care, training, remote learning, and much more. We are happy to broaden our support of the healthcare industry by entering the medical device market, particularly the rapidly growing field of bioelectronic medicine."

Vuzix is a leading supplier of Smart-Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets. The company's products include personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays, and augmented reality.

The company holds 179 patents and patents pending and numerous IP licenses in the Video Eyewear field and has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2020 and several wireless technology innovation awards among others.

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. The company's first product, PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory

Contact the author at [jon.hopkins@proactiveinvestors.com](mailto:jon.hopkins@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of BioSig Technologies, Inc. named herein, including the promotion by the Company of BioSig Technologies, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).